V114 pneumococcal conjugate vaccine candidate : Merck has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for V114, its 15-valent pneumococcal conjugate vaccine candidate. The Merck vaccine candidate is intended for use in adults 18 years of age and older. The pharma giant said that it […]
Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s investigational Covid-19 drug – CD24Fc. Based in Maryland, OncoImmune is a clinical-stage biopharma company, that is focused on the discovery and development of therapies for cancer and autoimmune disease. As […]
Continue reading …Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]
Continue reading …US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]
Continue reading …Pharma giant Merck has wrapped up its previously announced acquisition of Austrian vaccine developer Themis Bioscience. The Austrian company is focused on developing vaccines and immune-modulation therapies for infectious diseases and cancer. Merck announced the deal last month in a move to gain access to Themis Bioscience’s coronavirus vaccine candidate. Read more about Merck acquisition […]
Continue reading …Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an objective to gain access to the latter’s coronavirus vaccine candidate. Themis Bioscience by leveraging its measles virus vector platform has developed a pipeline of vaccine candidates and immune-modulatory therapies. Recently, […]
Continue reading …PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]
Continue reading …Merck has broken ground on the €250 million Merck Biotech Development Center, a new biotech development facility in Switzerland at Corsier-sur-Vevey. The new facility will be used for biotech development and manufacturing for clinical studies. Construction on the biotech development facility is likely to be wrapped up next year with full operations to begin by […]
Continue reading …Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]
Continue reading …